Cargando…

Standardized Human Platelet Lysates as Adequate Substitute to Fetal Calf Serum in Endothelial Cell Culture for Tissue Engineering

Fetal calf serum (FCS) is used for in vitro cell culture, as it provides the cells with various growth-promoting compounds. For applications in humans, FCS does not meet the required safety standards and should be replaced by an appropriate substitute. This study analyzed the suitability of using hu...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters, Katharina, Helmert, Tania, Gebhard, Susanne, Mailänder, Volker, Unger, Ronald E., Nezi-Cahn, Sandra, Hasenburg, Annette, Heller, Martin, Schwab, Roxana, Brenner, Walburgis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913112/
https://www.ncbi.nlm.nih.gov/pubmed/35281595
http://dx.doi.org/10.1155/2022/3807314
_version_ 1784667348061388800
author Peters, Katharina
Helmert, Tania
Gebhard, Susanne
Mailänder, Volker
Unger, Ronald E.
Nezi-Cahn, Sandra
Hasenburg, Annette
Heller, Martin
Schwab, Roxana
Brenner, Walburgis
author_facet Peters, Katharina
Helmert, Tania
Gebhard, Susanne
Mailänder, Volker
Unger, Ronald E.
Nezi-Cahn, Sandra
Hasenburg, Annette
Heller, Martin
Schwab, Roxana
Brenner, Walburgis
author_sort Peters, Katharina
collection PubMed
description Fetal calf serum (FCS) is used for in vitro cell culture, as it provides the cells with various growth-promoting compounds. For applications in humans, FCS does not meet the required safety standards and should be replaced by an appropriate substitute. This study analyzed the suitability of using human platelet lysate (hPL) as a substitute for FCS in endothelial cell cultures for in vitro and in vivo tissue engineering applications. The focus was placed on standardized, commercially available hPLs (MultiPL'30, MultiPL'100), which are approved for applications in humans, and compared to laboratory-prepared hPLs (lp-hLP). Human umbilical vein endothelial cells (HUVEC) were cultured with FCS or with different hPLs. Cell morphology, proliferation, viability, apoptosis, and necrosis, as well as the organization of vascular structures, were assessed. No morphological changes were noticed when FCS was replaced by standardized hPLs in concentrations of 1-10%. In contrast, the use of lp-hLPs led to irregular cell shape and increased vacuolization of the cytoplasm. HUVEC proliferation and viability were not compromised by using media supplemented with standardized hPLs or pl-hPLs in concentrations of 1-10%, compared to cells grown in media supplemented with 20% FCS. The apoptosis rate using lp-hPLs was higher compared to the use of standardized hPLs. The necrosis rate tended to be lower when FCS was replaced by hPLs. HUVEC formed more pronounced capillary-like structures when the media were supplemented with hPLs instead of supplementation with FCS. Thus, compared to the use of FCS, the use of hPLs was beneficial for the growth and optimal expression of functional endothelial cell characteristics during in vitro experiments. Commercially available hPLs proved to be particularly suitable, as they led to reproducible results during in vitro experiments, while meeting the safety requirements for in vivo use.
format Online
Article
Text
id pubmed-8913112
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-89131122022-03-11 Standardized Human Platelet Lysates as Adequate Substitute to Fetal Calf Serum in Endothelial Cell Culture for Tissue Engineering Peters, Katharina Helmert, Tania Gebhard, Susanne Mailänder, Volker Unger, Ronald E. Nezi-Cahn, Sandra Hasenburg, Annette Heller, Martin Schwab, Roxana Brenner, Walburgis Biomed Res Int Research Article Fetal calf serum (FCS) is used for in vitro cell culture, as it provides the cells with various growth-promoting compounds. For applications in humans, FCS does not meet the required safety standards and should be replaced by an appropriate substitute. This study analyzed the suitability of using human platelet lysate (hPL) as a substitute for FCS in endothelial cell cultures for in vitro and in vivo tissue engineering applications. The focus was placed on standardized, commercially available hPLs (MultiPL'30, MultiPL'100), which are approved for applications in humans, and compared to laboratory-prepared hPLs (lp-hLP). Human umbilical vein endothelial cells (HUVEC) were cultured with FCS or with different hPLs. Cell morphology, proliferation, viability, apoptosis, and necrosis, as well as the organization of vascular structures, were assessed. No morphological changes were noticed when FCS was replaced by standardized hPLs in concentrations of 1-10%. In contrast, the use of lp-hLPs led to irregular cell shape and increased vacuolization of the cytoplasm. HUVEC proliferation and viability were not compromised by using media supplemented with standardized hPLs or pl-hPLs in concentrations of 1-10%, compared to cells grown in media supplemented with 20% FCS. The apoptosis rate using lp-hPLs was higher compared to the use of standardized hPLs. The necrosis rate tended to be lower when FCS was replaced by hPLs. HUVEC formed more pronounced capillary-like structures when the media were supplemented with hPLs instead of supplementation with FCS. Thus, compared to the use of FCS, the use of hPLs was beneficial for the growth and optimal expression of functional endothelial cell characteristics during in vitro experiments. Commercially available hPLs proved to be particularly suitable, as they led to reproducible results during in vitro experiments, while meeting the safety requirements for in vivo use. Hindawi 2022-03-03 /pmc/articles/PMC8913112/ /pubmed/35281595 http://dx.doi.org/10.1155/2022/3807314 Text en Copyright © 2022 Katharina Peters et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The publication of this article was funded by Max Planck.
spellingShingle Research Article
Peters, Katharina
Helmert, Tania
Gebhard, Susanne
Mailänder, Volker
Unger, Ronald E.
Nezi-Cahn, Sandra
Hasenburg, Annette
Heller, Martin
Schwab, Roxana
Brenner, Walburgis
Standardized Human Platelet Lysates as Adequate Substitute to Fetal Calf Serum in Endothelial Cell Culture for Tissue Engineering
title Standardized Human Platelet Lysates as Adequate Substitute to Fetal Calf Serum in Endothelial Cell Culture for Tissue Engineering
title_full Standardized Human Platelet Lysates as Adequate Substitute to Fetal Calf Serum in Endothelial Cell Culture for Tissue Engineering
title_fullStr Standardized Human Platelet Lysates as Adequate Substitute to Fetal Calf Serum in Endothelial Cell Culture for Tissue Engineering
title_full_unstemmed Standardized Human Platelet Lysates as Adequate Substitute to Fetal Calf Serum in Endothelial Cell Culture for Tissue Engineering
title_short Standardized Human Platelet Lysates as Adequate Substitute to Fetal Calf Serum in Endothelial Cell Culture for Tissue Engineering
title_sort standardized human platelet lysates as adequate substitute to fetal calf serum in endothelial cell culture for tissue engineering
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8913112/
https://www.ncbi.nlm.nih.gov/pubmed/35281595
http://dx.doi.org/10.1155/2022/3807314
work_keys_str_mv AT peterskatharina standardizedhumanplateletlysatesasadequatesubstitutetofetalcalfseruminendothelialcellculturefortissueengineering
AT helmerttania standardizedhumanplateletlysatesasadequatesubstitutetofetalcalfseruminendothelialcellculturefortissueengineering
AT gebhardsusanne standardizedhumanplateletlysatesasadequatesubstitutetofetalcalfseruminendothelialcellculturefortissueengineering
AT mailandervolker standardizedhumanplateletlysatesasadequatesubstitutetofetalcalfseruminendothelialcellculturefortissueengineering
AT ungerronalde standardizedhumanplateletlysatesasadequatesubstitutetofetalcalfseruminendothelialcellculturefortissueengineering
AT nezicahnsandra standardizedhumanplateletlysatesasadequatesubstitutetofetalcalfseruminendothelialcellculturefortissueengineering
AT hasenburgannette standardizedhumanplateletlysatesasadequatesubstitutetofetalcalfseruminendothelialcellculturefortissueengineering
AT hellermartin standardizedhumanplateletlysatesasadequatesubstitutetofetalcalfseruminendothelialcellculturefortissueengineering
AT schwabroxana standardizedhumanplateletlysatesasadequatesubstitutetofetalcalfseruminendothelialcellculturefortissueengineering
AT brennerwalburgis standardizedhumanplateletlysatesasadequatesubstitutetofetalcalfseruminendothelialcellculturefortissueengineering